Navigation Links
SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
Date:9/12/2007

ISELIN, N.J., Sept. 12 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD.OB), today announced that it will host a symposium entitled "Post-Operative Adhesions in Cardiac Surgery: Challenges and Solutions" for surgeons attending next week's European Association for Cardio- Thoracic Surgery Annual Meeting in Geneva, Switzerland. The symposium will be chaired by Professor Stephen Westaby of the John Radcliffe Hospital in Oxford, United Kingdom and will include presentations by principal investigators who participated in US and European clinical trials for REPEL-CV(R) Adhesion Barrier, the company's novel bioresorbable film intended to reduce the formation of adhesions (scar tissue) in cardiac surgical procedures. Professor Westaby stated, "It is important to inform our surgeon colleagues that, with REPEL-CV, we now appear to a have way of reducing patient risks associated with the presence of adhesions during cardiac reoperations."

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, including statements regarding indications of the timing or ability to achieve regulatory approval and market launch for REPEL-CV or the potential market size for REPEL-CV, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the Company's efforts to obtain and maintain required FDA and other regulatory approvals; (ii) potential inability to secure funding as and when needed to support the Company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Symposium will include venture capital "coaching"
2. Fusion 2006 symposium focuses on making IT work for businesses
3. Early Stage Symposium session will help emerging companies prepare for investors
4. Food microbiology symposium will mark 25 years
5. High interest forces delay in food safety symposium
6. Milwaukee to host inaugural Great Lakes Agro-Security Symposium
7. Fusion 2005 symposium aims to bring CIOs to the boardroom
8. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
9. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
10. Symposium examines the effect of race on genetics and disease
11. Belmont Report Commission reuniting for Medical College of Wisconsin Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 ... announced today expansion of its translational research program ... through establishment of laboratory facilities in San Diego.  ... San Diego BioLabs facility, a biotechnology incubator sponsored ... Sanofi. In November 2016, the Company ...
(Date:2/21/2017)... Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... protect and restore the health of patients, intends to report operational ... on Thursday, March 2, 2017, and to host a conference call ... the call is as follows: U.S. (toll free): 1-888-347-5280 ... ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... organizations to build connected digital health applications, announced a partnership with Redox, a ... to seamlessly connect to many clinical systems while keeping data secure in the ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... and development (R&D), today announced the establishment of Genedata Limited as a new ... Teburi, a recognized expert in life science informatics. Creating the UK subsidiary reinforces ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/23/2017)... -- The latest mobile market research from Acuity Market Intelligence ... quarterly average price of a biometric smartphone decreased from ... There are now 120 sub-$150 models on the market ... 28 a year ago at an average price of ... , Acuity Market Intelligence Principal, "Biometric Smartphones are a ...
Breaking Biology News(10 mins):